{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:10:09Z","timestamp":1790021409792,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clnesp.2026.105040","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:10:21Z","timestamp":1787267421000},"page":"105040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8912-5882","authenticated-orcid":false,"given":"Maho","family":"Egusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-5042","authenticated-orcid":false,"given":"Issei","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Shimose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohji","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10504","key":"10.1016\/j.clnesp.2026.105040_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The lancet commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clnesp.2026.105040_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.clnesp.2026.105040_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clnesp.2026.105040_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"10492","key":"10.1016\/j.clnesp.2026.105040_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clnesp.2026.105040_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clnesp.2026.105040_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clnesp.2026.105040_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00535-018-1532-5","article-title":"A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011\u20132015 update","volume":"54","author":"Tateishi","year":"2019","journal-title":"J Gastroenterol"},{"issue":"Supplement","key":"10.1016\/j.clnesp.2026.105040_bib9","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"9612","key":"10.1016\/j.clnesp.2026.105040_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"issue":"10352","key":"10.1016\/j.clnesp.2026.105040_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the global burden of disease study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.clnesp.2026.105040_bib12","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i19.105617","article-title":"Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma","volume":"31","author":"Sierra","year":"2025","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.clnesp.2026.105040_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70494","article-title":"Obesity paradox in cancer: a complex interplay between risk and therapeutic outcomes","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.clnesp.2026.105040_bib15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/liv.15885","article-title":"Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab","volume":"44","author":"Rimini","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.clnesp.2026.105040_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.978110","article-title":"Association between sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Jiang","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnesp.2026.105040_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clnesp.2022.04.009","article-title":"Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis","volume":"49","author":"March","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"6","key":"10.1016\/j.clnesp.2026.105040_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218136","article-title":"Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparison with sorafenib therapy","volume":"14","author":"Saeki","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.clnesp.2026.105040_bib19","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3390\/cancers13092247","article-title":"Skeletal muscle volume is an independent predictor of survival after sorafenib treatment failure for hepatocellular carcinoma","volume":"13","author":"Saeki","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clnesp.2026.105040_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000487858","article-title":"No muscle depletion with high visceral fat as a novel beneficial biomarker of sorafenib for hepatocellular carcinoma","volume":"7","author":"Saeki","year":"2018","journal-title":"Liver Cancer"},{"issue":"3","key":"10.1016\/j.clnesp.2026.105040_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000527402","article-title":"Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients: multicenter analysis","volume":"12","author":"Hiraoka","year":"2023","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.clnesp.2026.105040_bib22","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/cancers15092426","article-title":"Prevalence and effect of low skeletal muscle mass among hepatocellular carcinoma patients undergoing systemic therapy: a systematic review and meta-analysis","volume":"15","author":"Kuo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clnesp.2026.105040_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.clnesp.2026.105040_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hepr.12774","article-title":"Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/07853890.2010.526138","article-title":"Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study)","volume":"44","author":"Hiuge-Shimizu","year":"2012","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","article-title":"Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography","volume":"85","author":"Mitsiopoulos","year":"1998","journal-title":"J Appl Physiol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1148\/radiology.211.1.r99ap15283","article-title":"Abdominal fat: standardized technique for measurement at CT","volume":"211","author":"Yoshizumi","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.clnesp.2026.105040_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.567881","article-title":"Muscle-organ crosstalk: focus on immunometabolism","volume":"11","author":"Bay","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.clnesp.2026.105040_bib30","article-title":"Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.clnesp.2026.105040_bib31","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.3390\/jcm10225329","article-title":"Sarcopenia\u2019s prognostic impact on patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clnesp.2026.105040_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/cells13030252","article-title":"Molecular mechanisms of cachexia: a review","volume":"13","author":"Neshan","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105040_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41392-022-01116-6","article-title":"Supporting tumor therapy by exercise: boosting T cell immunity by myokines","volume":"7","author":"Gebhardt","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"10","key":"10.1016\/j.clnesp.2026.105040_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258831","article-title":"Effect of immune modulation on the skeletal muscle mitochondrial exercise response: an exploratory study in mice with cancer","volume":"16","author":"Buss","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clnesp.2026.105040_bib36","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1002\/jcsm.13371","article-title":"High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers","volume":"14","author":"Liu","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnesp.2026.105040_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101778","article-title":"Thresholds of handgrip strength for all-cause, cancer, and cardiovascular mortality: a systematic review with dose-response meta-analysis","volume":"82","author":"L\u00f3pez-Bueno","year":"2022","journal-title":"Ageing Res Rev"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726021376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726021376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:32:53Z","timestamp":1790019173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726021376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S2405457726021376"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.105040","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.105040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}],"article-number":"105040"}}